Claude Linassier

6.5k total citations
97 papers, 2.7k citations indexed

About

Claude Linassier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Claude Linassier has authored 97 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 22 papers in Pathology and Forensic Medicine. Recurrent topics in Claude Linassier's work include Lymphoma Diagnosis and Treatment (16 papers), Renal cell carcinoma treatment (11 papers) and Sarcoma Diagnosis and Treatment (10 papers). Claude Linassier is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Renal cell carcinoma treatment (11 papers) and Sarcoma Diagnosis and Treatment (10 papers). Claude Linassier collaborates with scholars based in France, United States and Slovakia. Claude Linassier's co-authors include Judit Markovits, Alain Jacquemin‐Sablon, Philippe Fossé, Annette K. Larsen, J Pierre, Jean Bernard Le Pecq, Jean‐Bernard Le Pecq, Josiane Pierre, Michel Pierre and Pierre Dubois and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Claude Linassier

93 papers receiving 2.7k citations

Peers

Claude Linassier
D L Trump United States
Christian Dittrich Austria
Hisakazu Yamagishi Japan
Ramzi Dagher United States
Denice Tsao‐Wei United States
Steven Weitman United States
David A. Van Echo United States
Frances Boxall United Kingdom
Jacques Jolivet Canada
R B Weiss United States
D L Trump United States
Claude Linassier
Citations per year, relative to Claude Linassier Claude Linassier (= 1×) peers D L Trump

Countries citing papers authored by Claude Linassier

Since Specialization
Citations

This map shows the geographic impact of Claude Linassier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claude Linassier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claude Linassier more than expected).

Fields of papers citing papers by Claude Linassier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claude Linassier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claude Linassier. The network helps show where Claude Linassier may publish in the future.

Co-authorship network of co-authors of Claude Linassier

This figure shows the co-authorship network connecting the top 25 collaborators of Claude Linassier. A scholar is included among the top collaborators of Claude Linassier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claude Linassier. Claude Linassier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ouldamer, Lobna, et al.. (2024). Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature. The Oncologist. 29(7). e910–e917. 1 indexed citations
2.
Chamorey, Emmanuel, Jean-­Marc Ferrero, Hakim Mahammedi, et al.. (2024). Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences. 25(11). 6058–6058.
3.
4.
Ferrero, Jean-­Marc, Hakim Mahammedi, Gwénaëlle Gravis, et al.. (2023). Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics. 15(2). 651–651. 3 indexed citations
5.
6.
Blay, Jean‐Yves, Sylvie Chevret, Nicolas Penel, et al.. (2020). 1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study. Annals of Oncology. 31. S972–S972. 9 indexed citations
7.
Marec‐Bérard, Perrine, Valérie Laurence, Bob‐Valéry Occéan, et al.. (2019). Methotrexate–Etoposide–Ifosfamide Compared with Doxorubicin–Cisplatin–Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18–25 Years. Journal of Adolescent and Young Adult Oncology. 9(2). 172–182. 12 indexed citations
8.
9.
Cesne, Axel Le, Isabelle Ray‐Coquard, Florence Duffaud, et al.. (2015). Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. European Journal of Cancer. 51(6). 742–750. 80 indexed citations
10.
Gonçalvès, Anthony, Jean‐Yves Pierga, Jean-­Marc Ferrero, et al.. (2015). UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Annals of Oncology. 26(8). 1692–1697. 14 indexed citations
11.
Brunereau, L., F. Bruyère, Claude Linassier, & Jean‐Louis Baulieu. (2012). The role of imaging in staging and monitoring testicular cancer. Diagnostic and Interventional Imaging. 93(4). 310–318. 20 indexed citations
12.
Oudard, Stéphane, Olivier Rixe, Benoit Beuselinck, et al.. (2010). A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunology Immunotherapy. 60(2). 261–271. 71 indexed citations
13.
Linassier, Claude, B Desablens, Thierry Lefrancq, et al.. (2002). Stage I-IIE Primary Non-Hodgkin's Lymphoma of the Testis: Results of a Prospective Trial by the GOELAMS Study Group. Clinical Lymphoma. 3(3). 167–172. 32 indexed citations
14.
Bennouna, Jaafar, R. Delva, F. Gómez, et al.. (2002). A Phase II Study with 5-Fluorouracil, Folinic Acid and Oxaliplatin (FOLFOX-4 Regimen) in Patients with Metastatic Renal Cell Carcinoma. Oncology. 64(1). 25–27. 12 indexed citations
15.
Benboubker, Lotfi, Claude Linassier, Martine Delain, et al.. (1998). Mediastinal Large-Cell Lymphoma with Sclerosis Refractory to Conventional Chemotherapy can Respond after Daily Oral Cyclophosphamide. Leukemia & lymphoma. 29(1-2). 199–203. 1 indexed citations
16.
Delain, Martine, Claude Linassier, Philippe Goupille, et al.. (1994). VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.. Journal of Clinical Oncology. 12(12). 2706–2713. 4 indexed citations
17.
18.
Colombat, P, C Binet, Claude Linassier, et al.. (1992). High Dose Chemotherapy with Autologous Marrow Transplantation in Follicular Lymphomas. Leukemia & lymphoma. 7(sup1). 3–6. 12 indexed citations
19.
Linassier, Claude, et al.. (1992). Simultaneous occurrence of acute myelogenous leukemia and seminoma of the testis. Cancer Chemotherapy and Pharmacology. 30(3). 233–234. 4 indexed citations
20.
Colombat, Philippe, F Fétissof, G. Calais, et al.. (1990). [Primary non-Hodgkin's high grade malignant lymphoma of the digestive system. A prospective study of the combination of surgery-chemotherapy-radiotherapy].. PubMed. 77(8). 811–20. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D L Trump Breakdown of academic impact, for papers by Christian Dittrich Breakdown of academic impact, for papers by Hisakazu Yamagishi Breakdown of academic impact, for papers by Ramzi Dagher Breakdown of academic impact, for papers by Denice Tsao‐Wei Breakdown of academic impact, for papers by Steven Weitman Breakdown of academic impact, for papers by David A. Van Echo Breakdown of academic impact, for papers by Frances Boxall Breakdown of academic impact, for papers by Jacques Jolivet Breakdown of academic impact, for papers by R B Weiss
Rankless by CCL
2026